We are pleased to announce that the following ESOT Sections and Committees launched a call for nominations for new Board members: EKITA, ELITA, VCA, BSC, YPT
ESOT Sections and Committees – Open Call for Nominations 2026
We are pleased to announce that the following ESOT Sections and Committees launched a call for nominations for new Board members: EKITA, ELITA, VCA, BSC, YPT
The Vascularized Composite Allotransplantation (VCA) Section is pleased to announce a call for nominations for four new Board members. The elected members will serve two years (2026-2028) with a maximum of two consecutive terms. One of the four positions is reserved for a professional working in the field of uterus transplantation.
YPT – The Young Professionals in Transplantation Committee – would like to announce a call for nominations for two Board members. The new YPT Board Members will hold office for four years (2026–2030), starting in September 2026.
BSC – the Basic Science Committee- would like to announce a call for nominations for one Board member. The new BSC Board Members will hold office for four years (2026-2030), starting in September 2026.
EKITA, the European Kidney Transplant Section of ESOT, would like to announce a call for nominations for one new Board member. The new EKITA Board Member will hold office for four years (2026-2030), starting in September 2026.
ELITA – the European Liver and Intestine Transplant Association – would like to announce a call for nominations for one new Board member. The new ELITA Board Member will hold office for four years (2026-2030), starting in September 2026.
A new Delphi initiative is seeking experienced clinicians in solid-organ transplantation to contribute to a European consensus project. The study will use structured, multi-round surveys to gather expert opinions, identify key challenges, and build consensus on current practices in the field. Findings will help inform future guidance and support harmonised care across Europe. Key points:
You are invited to take part in this survey, designed by a panel of CMV experts selected by ESOT. The findings will contribute to a scientific peer-reviewed publication and help build a clearer picture of real-world practice across transplant centres.
Chronic Lung Allograft Dysfunction (CLAD) remains one of the most serious long-term complications after lung transplantation. While transplantation can be life-saving,CLAD presents ongoing medical, physical, and emotional challenges for patients, caregivers, and healthcare professionals. Join our upcoming free webinar in the CLAD series! This expert-led session will provide an updated overview of the burden of CLAD, focusing
EPITR is the result of years of collaboration and careful learning. We have built a registry that advances science while putting data protection, ethical governance, and patient safety at its core. This balance is essential if real-world data is to truly serve patients and guide the future of transplantation. Devi Mey, ESOT CEO